Ensign Peak Advisors
VKTX icon

Ensign Peak Advisors’s Viking Therapeutics VKTX Stock Holding History

Ensign Peak Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$304K Buy
7,789
+850
+12% +$27.5K ﹤0.01% 1172
2026
Q1 		$226K Hold
6,939
– – ﹤0.01% 1261
2025
Q4 		$244K Sell
6,939
-10,850
-61% -$384K ﹤0.01% 1214
2025
Q3 		$467K Sell
17,789
-18,900
-52% -$564K ﹤0.01% 1411
2025
Q2 		$972K Sell
36,689
-136,201
-79% -$3.59M ﹤0.01% 1258
2025
Q1 		$4.18M Sell
172,890
-239,766
-58% -$7.58M 0.01% 673
2024
Q4 		$16.6M Sell
412,656
-39,355
-9% -$2.24M 0.03% 352
2024
Q3 		$28.6M Hold
452,011
– – 0.05% 264
2024
Q2 		$24M Buy
452,011
+165,851
+58% +$10.9M 0.04% 285
2024
Q1 		$23.5M Sell
286,160
-2,111
-0.7% -$93.9K 0.04% 298
2023
Q4 		$5.36M Buy
288,271
+1,650
+0.6% +$21.6K 0.01% 611
2023
Q3 		$3.17M Buy
286,621
+14,200
+5% +$203K 0.01% 693
2023
Q2 		$4.42M Buy
272,421
+28,100
+12% +$589K 0.01% 620
2023
Q1 		$4.07M Buy
+244,321
New +$2.52M 0.01% 625

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ensign Peak Advisors's VKTX Position: Q2 2026 in Review

Ensign Peak Advisors increased its Viking Therapeutics (VKTX) stake by 12% in Q2 2026, buying an estimated $27.5K and bringing the position to 7,789 shares worth $304K. The position accounts for ﹤0.01% of the portfolio, ranked #1172.

Ensign Peak Advisors first reported a position in VKTX in Q1 2023 and has held it in 14 quarters since. The position peaked at $28.6M in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Ensign Peak Advisors held 7,789 shares of Viking Therapeutics worth $304K as of Q2 2026.
  • Ensign Peak Advisors bought 850 Viking Therapeutics shares in Q2 2026, an estimated $27.5K.
  • Viking Therapeutics made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1172 holding.
  • Ensign Peak Advisors first reported a position in Viking Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Ensign Peak Advisors's Viking Therapeutics position peaked at $28.6M in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.